2696 Stock Overview
Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Shanghai Henlius Biotech, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$21.50 |
52 Week High | HK$23.45 |
52 Week Low | HK$11.20 |
Beta | 0.83 |
11 Month Change | -1.83% |
3 Month Change | -7.33% |
1 Year Change | 60.21% |
33 Year Change | -16.34% |
5 Year Change | -47.30% |
Change since IPO | -56.52% |
Recent News & Updates
Recent updates
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
May 25Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 25Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking
Mar 10Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load
Dec 31The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business
Nov 25Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
Sep 18Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet
Aug 03Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?
May 31Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues
Apr 06Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
Sep 22Shareholder Returns
2696 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 2.9% | 3.1% | 0.3% |
1Y | 60.2% | -12.4% | 13.1% |
Return vs Industry: 2696 exceeded the Hong Kong Biotechs industry which returned -12.4% over the past year.
Return vs Market: 2696 exceeded the Hong Kong Market which returned 13.1% over the past year.
Price Volatility
2696 volatility | |
---|---|
2696 Average Weekly Movement | 2.5% |
Biotechs Industry Average Movement | 11.0% |
Market Average Movement | 8.9% |
10% most volatile stocks in HK Market | 19.0% |
10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2696 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2696's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 3,546 | Jason Zhu | www.henlius.com |
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer; and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous-cell carcinomas, gastric cancer, small cell lung cancer, hepatocellular carcinoma, metastatic colorectal cancer, solid tumors, SCCHN, sqNSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, and HLX51 to treat solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; and HLX14 to treat osteoporosis.
Shanghai Henlius Biotech, Inc. Fundamentals Summary
2696 fundamental statistics | |
---|---|
Market cap | HK$11.69b |
Earnings (TTM) | HK$740.67m |
Revenue (TTM) | HK$6.03b |
15.8x
P/E Ratio1.9x
P/S RatioIs 2696 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2696 income statement (TTM) | |
---|---|
Revenue | CN¥5.64b |
Cost of Revenue | CN¥1.51b |
Gross Profit | CN¥4.13b |
Other Expenses | CN¥3.44b |
Earnings | CN¥692.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.27 |
Gross Margin | 73.23% |
Net Profit Margin | 12.27% |
Debt/Equity Ratio | 147.0% |
How did 2696 perform over the long term?
See historical performance and comparison